Abstract:Background: Dendritic cell (DC) targeted antigen delivery is a promising strategy to enhance vaccine efficacy and delivery of therapeutics. Self-assembling peptide-based nanoparticles and virus-like particles (VLPs) have attracted extensive interest as non replicating vectors for nanovaccine design, based on their unique properties, including molecular specificity, biodegradability and biocompatibility. DCs are specialized antigen-presenting cells involved in antigen capture, processing, and presentation to initiate adaptive immune responses. Using DC-specific ligands for targeted delivery of antigens to DCs may be utilized as a promising strategy to drive efficient and strong immune responses. Methods: In this study, several candidates for DC-binding peptides (DCbps) were individually integrated into C-terminal of porcine circovirus type 2 (PCV2) Cap, a viral protein that could self-assemble into icosahedral VLPs with 60 subunits. The immunostimulatory adjuvant activity of DC-targeted VLPs was further evaluated in a vaccine model of PCV2 Cap. Results: With transmission electron microscopy (TEM), E. coli expressed Cap-DCbp fusion proteins were observed self-assembled into highly ordered VLPs. Further, in dynamic light scattering (DLS) analysis, chimeric VLPs exhibited similar particle size uniformity and narrow size distribution as compared to wild type Cap VLPs. With a distinctly higher targeting efficiency, DCbp3 integrated Cap VLPs (Cap-DCbp3) displayed enhanced antigen uptake and increased elicitation of antigen presentation-related factors in BM-DCs. Mice subcutaneously immunized with Cap-DCbp3 VLPs exhibited significantly higher levels of Cap-specific antibodies, neutralizing antibodies and intracellular cytokines than those with other DCbp integrated or wild type Cap VLPs without any DCbp. Interestingly, Cap-DCbp3 VLPs vaccine induces robust cellular immune response profile, including the efficient production of IFN-gamma, IL-2 and IL-10. Meanwhile, the improved proliferation index in lymphocytes with Cap-DCbp3 was also detected as compared to other VLPs. Conclusion: This study described the potential of DC-binding peptides for further improved antigen delivery and vaccine efficacy, explainning nanovaccine optimization in relation to a range of emerging and circulating infectious pathogens.

Overcoming Biological Barriers by Virus-Like Drug Particles for Drug Delivery.

Virus-like particle-based nanocarriers as an emerging platform for drug delivery

Virus-Like Particle Engineering: From Rational Design to Versatile Applications

Tailored Viral-Like Particles as Drivers of Medical Breakthroughs

Gene-free Viral-like particles (VLPs) offer a safer alternative to inactivating or weakening viral strains for traditional vaccines. VLP-based vaccinations without adjuvants have been found to promote humoral and cellular immunity

Virus-like particles: flexible platforms for vaccine development

Virus-like particles as powerful vaccination strategy against human viruses

Targeted Delivery of Nanovaccine to Dendritic Cells Via DC-Binding Peptides Induces Potent Antiviral Immunity in Vivo

Virus-like particles: models for assembly studies and foreign epitope carriers

Platforms, advances, and technical challenges in virus-like particles-based vaccines

Biomimetic bacterial and viral-based nanovesicles for drug delivery, theranostics, and vaccine applications

Viral Nanoparticles‐Mediated Delivery of Therapeutic Cargo

[Current research status of virus-like particle vaccine]

Micro Trojan horses: Engineering extracellular vesicles crossing biological barriers for drug delivery

Virus-like Particle Vaccines and Platforms for Vaccine Development

Virus-like particles with removable cyclodextrins enable glutathione-triggered drug release in cells

Virus-like particles: The new frontier of vaccines for animal viral infections

Drug Delivery: Virus-Inspired Mimics Based on Dendritic Lipopeptides for Efficient Tumor-Specific Infection and Systemic Drug Delivery (adv. Funct. Mater. 33/2015)

Liposome-Mediated Anti-Viral Drug Delivery Across Blood-Brain Barrier: Can Lipid Droplet Target Be Game Changers?

Sequential administration of virus-like particle-based nanomedicine to elicit enhanced tumor chemotherapy

Biomimetic engineered nanocarriers inspired by viruses for oral-drug delivery